Imatinib Cf (Imatinib)

Imatinib works by binding to the ATP‑binding pocket of specific tyrosine kinases such as BCR‑ABL, c‑KIT and PDGFR. This blocks phosphorylation of downstream proteins, halting the signalling pathways that promote uncontrolled cell division and survival, ultimately leading to cancer cell death while largely sparing normal cells.

The appropriate dose of Imatinib Cf is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and any concomitant medications. Dosage regimens are not standardized in public literature and must be set by a qualified healthcare professional.

Data on imatinib use in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk to the fetus or infant. Women of child‑bearing potential should discuss contraception with their physician, and breastfeeding is not recommended while receiving imatinib.

To request Imatinib Cf, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to imatinib within the same therapeutic class is dasatinib, another BCR‑ABL inhibitor. Dasatinib has a broader kinase inhibition profile and may be effective in some imatinib‑resistant cases, but it also carries a different safety spectrum, including higher rates of pleural effusion. Choice between them depends on disease characteristics, prior therapy response and individual patient tolerance.

Imatinib Cf should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, excessive heat and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Imatinib is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to maintain consistent absorption.

The most serious adverse events associated with imatinib include severe neutropenia, hepatotoxicity (significant liver enzyme elevations or liver failure), and cardiac failure, especially in patients with pre‑existing heart disease. Prompt reporting of symptoms such as fever, jaundice, shortness of breath or swelling of the legs is essential for early intervention.

Imatinib is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Patients with uncontrolled cardiac disease, severe hepatic impairment, or those taking certain strong CYP3A4 inducers or inhibitors that cannot be managed may also be advised against its use. Clinical judgment is required to assess suitability.